OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Psychopharmacology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	296
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	219
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	133
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder	120
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	89
Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning	82
The chronic effects of a combination of herbal extracts (Euphytose^®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	77
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	66
Relationship between depression, prefrontal creatine and grey matter volume	62
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a	54
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	52
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report	49
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	46
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	45
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	44
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	43
Psychedelics and the ‘inner healer’: Myth or mechanism?	43
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	42
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	41
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	38
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment	38
Repurposing psychopharmacology: A two-way street?	38
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	37
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	37
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	36

A framework for assessment of adverse events occurring in psychedelic-assisted therapies	36
Effects of 31 recombinant CYP2C19 variants on clomipramine metabolism in vitro	36
The effects of antenatal depression and SSRI exposure on children: A systematic review	34
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	34
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	32
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	31
What are set and setting: Reducing vagueness to improve research and clinical practice	31
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	31
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	31